Related Experiment Videos
Replacement of the p16 gene in human ovarian cancer cells
1Department of Obstetrics and Gynecology, Second Clinical College of China Medical University, Shenyang 110003, China. wm21st@hotmail.com
Objective:
To study the inhibitory effects of retrovirus-mediated p16 gene on the human ovarian cancer cell line CAOV3.
Methods:
The recombinant eukaryotic expression vector pDOR-p16 containing exogenous human wt-p16 cDNA and vector with neomycin resistance gene only were introduced into a CAOV3 cell line which does not express p16 endogenously by lipofectamine-mediated gene transfection. By using polymerase chain reaction amplification, mRNA in situ hybridization and immunocytochemistry, the clones obtained were tested for their efficiency of transfection and effects of vector expression. Their biologic behavior was observed further.
Results:
Exogenous wt-p16 was transferred into CAOV3 cells successfully and permanent expression was obtained. The growth rate of the transfected CAOV3 cells in regular medium and soft agar was inhibited, and the tumorigenicity in nude mice showed that two of four mice failed to form tumors, and the others developed tumors 7 to 14 days later than mice of the contrast group. The percentage of phase G1 cells increased and that of phase S cells decreased. Under electron microscope, the ultrastructural changes of the cells revealed necrosis and growth retardation.
Conclusions:
The p16 gene plays an important role in the generation and development of ovarian carcinoma. This study might provide experimental evidence for gene therapy in human ovarian cancer.
Insights
Introducing the p16 gene into human ovarian cancer cells (CAOV3) inhibited cell growth and tumor formation. This suggests the p16 gene
Area of Science:
- Molecular Biology
- Oncology
- Gene Therapy
Background:
- Ovarian cancer is a significant health concern.
- The p16 gene's role in ovarian cancer is not fully understood.
- CAOV3 is a human ovarian cancer cell line lacking endogenous p16 expression.
Purpose of the Study:
- To investigate the inhibitory effects of the p16 gene on the CAOV3 human ovarian cancer cell line.
- To assess the potential of p16 gene therapy for ovarian cancer.
Main Methods:
- Retrovirus-mediated delivery of the human wild-type p16 gene (wt-p16) into CAOV3 cells.
- Lipofectamine-mediated gene transfection.
- Confirmation of transfection and expression using polymerase chain reaction (PCR), mRNA in situ hybridization, and immunocytochemistry.
- Evaluation of biological behavior, including cell growth, soft agar colony formation, and tumorigenicity in nude mice.
Main Results:
- Successful transfer and permanent expression of the exogenous wt-p16 gene in CAOV3 cells.
- Significant inhibition of CAOV3 cell growth in vitro and in soft agar.
- Reduced tumorigenicity in nude mice, with delayed tumor formation in some cases.
- Cell cycle analysis showed an increase in G1 phase and a decrease in S phase.
- Ultrastructural analysis revealed cell necrosis and growth retardation.
Conclusions:
- The p16 gene plays a critical role in the development of ovarian carcinoma.
- Gene therapy utilizing the p16 gene shows promise for treating human ovarian cancer.
- This study provides experimental evidence supporting p16 gene therapy for ovarian cancer.